# A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Study · id `cardio:ct-nct07662135` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07662135](<https://clinicaltrials.gov/study/NCT07662135>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07662135

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 900 participants.

## Technical summary

Registry record NCT07662135. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-07-13 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 900 participants (planned count; ClinicalTrials.gov record NCT07662135, source copy `cardio:ctgov-nct07662135-2026-09-02`, retrieved 2026-10-26)
- Started: 2026-07-06 (actual) (ClinicalTrials.gov record NCT07662135, source copy `cardio:ctgov-nct07662135-2026-09-02`, retrieved 2026-10-26)
- Primary completion: 2028-07-13 (anticipated) (ClinicalTrials.gov record NCT07662135, source copy `cardio:ctgov-nct07662135-2026-09-02`, retrieved 2026-10-26)
- Completion: 2028-07-13 (anticipated) (ClinicalTrials.gov record NCT07662135, source copy `cardio:ctgov-nct07662135-2026-09-02`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; China; Denmark; Germany; India; Japan; Malaysia; Mexico; Spain; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT07662135, source copy `cardio:ctgov-nct07662135-2026-09-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07662135-2026-09-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Acronym: Eluminate-4
- Condition: Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes With Chronic Kidney Disease
- Intervention (Drug): Elecoglipron
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: c275863d028687e532b7b84389db172122d0b444e7711bec286ceb61810b72be
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
